Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30183-5 · Cited by 48,884

Clinical characteristics of coronavirus disease 2019 in China

Guan, W.-J., Ni, Z.-Y., Hu, Y., Liang, W.-H., Ou, C.-Q., He, J.-X., Liu, L., Shan, H., Lei, C.-L., Hui, D. S. C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2002032 · Cited by 30,246

A novel coronavirus from patients with pneumonia in China, 2019

Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244

Epidemiological and clinical characteristics of 99 cases of 2019 novel Coronavirus pneumonia in Wuhan, China: a descriptive study.

Chen, N., Zhou, M., Dong, X., Qu, J., Gong, F., Han, Y., Qiu, Y., Wang, J., Liu, Y., Wei, Y., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30211-7 · Cited by 21,415

Clinical characteristics of 138 hospitalized patients with 2019 Novel Coronavirus-Infected pneumonia in Wuhan, China

Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., et al. (2020) · JAMA · doi:10.1001/jama.2020.1585 · Cited by 20,148

La certeza de lo impredecible: Cultura Educación y Sociedad en tiempos de COVID19

Martínez González, M. (2020) · DSPACE System - Metalibrary (University of the Coast) · Cited by 18,463

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K. S. M., Lau, E. H. Y., Wong, J. Y., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001316 · Cited by 16,575

Pathological findings of COVID-19 associated with acute respiratory distress syndrome

Xu, Z., Shi, L., Wang, Y., Zhang, J., Huang, L., Zhang, C., Liu, S., Zhao, P., Liu, H., Zhu, L., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30076-x · Cited by 8,545

A Trial of Lopinavir–Ritonavir in Adults Hospitalized with Severe Covid-19

Cao, B., Wang, Y., Wen, D., Liu, W., Wang, J., Fan, G., Ruan, L., Song, B., Cai, Y., Wei, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001282 · Cited by 5,258

VEGF receptor signalling ? in control of vascular function

Olsson, A.-K., Dimberg, A., Kreuger, J., & Claesson-Welsh, L. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1911 · Cited by 3,122

Immunomodulatory therapy for the management of critically ill patients with COVID-19: A narrative review

Andaluz‐Ojeda, D., Vidal, P., Sanz, Á. A., Suberviola, B., Carbajo, L. D. R., Martín, L. N., Silva, E. P., Olmo, J. N.-D., Barberán, J., & Cusácovich, I. (2022) · World Journal of Critical Care Medicine · doi:10.5492/wjccm.v11.i4.269 · Cited by 6

Revisiting potential value of antitumor drugs in the treatment of COVID-19

Zheng, W., Zeng, Z., Lin, S., & Hou, P. (2022) · Cell & Bioscience · doi:10.1186/s13578-022-00899-z · Cited by 5

Host-Based Treatments for Severe COVID-19

Mondini, L., Salton, F., Trotta, L., Bozzi, C., Pozzan, R., Barbieri, M., Tavano, S., Lerda, S., Hughes, M., Confalonieri, M., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45040203 · Cited by 4

Severe COVID-19: Drugs and Clinical Trials

Ceja-Gálvez, H. R., Renteria-Flores, F. I., Nicoletti, F., Hernández‐Bello, J., Ojeda, G. M., & Muñóz-Valle, J. F. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082893 · Cited by 5

Interdisziplinäres COVID-Board bei SARS-CoV-2-getriggerter hyperferritinämischer Inflammation

Rosée, P. G. L., Bremer, H., Rosée, F. L., Mohm, P., Hochhaus, A., Gehrke, I., Kumle, B., Benzing, A., & Russo, S. G. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00750-8 · Cited by 4

A hitchhiker's guide through the COVID-19 galaxy

Felsenstein, S., & Reiff, A. O. (2021) · Clinical Immunology · doi:10.1016/j.clim.2021.108849 · Cited by 4

Common points of therapeutic intervention in COVID-19 and in allogeneic hematopoietic stem cell transplantation associated severe cytokine release syndrome

Gopcsa, L., Bobek, I., Bekő, G., Lakatos, B., Molnár, E., Réti, M., Remenyi, P. P., Sinkó, J., Szlávik, J., Tatai, G., et al. (2021) · Acta Microbiologica et Immunologica Hungarica · doi:10.1556/030.2021.01620 · Cited by 4

FDA approved five-membered ring fused pyrimidine-based derivatives and their biological properties

Kumar, M., Chatterjee, J., Rani, D., & Kumar, R. (2022) · Elsevier eBooks · doi:10.1016/b978-0-443-18616-5.00006-5 · Cited by 4

The difference in all-cause mortality between COVID-19 patients treated with standard of care plus placebo and those treated with standard of care alone: a network meta-analysis of randomised controlled trials of immunomodulatory kinase inhibitors

Tseng, P., Zeng, B., Hsu, C., Thompson, T., Stubbs, B., Hsueh, P., Su, K., Chen, Y., Chen, T., Wu, Y., et al. (2023) · Journal of the Royal Society of Medicine · doi:10.1177/01410768231202657 · Cited by 4

The use of remdesivir outside of clinical trials during the COVID-19 pandemic

Halimi, V., Daci, A., Ridova, N., Panovska-Stavridis, I., Stevanovic, M., Filipče, V., Dimovski, A. J., & Grozdanova, A. (2020) · Journal of Pharmaceutical Policy and Practice · doi:10.1186/s40545-020-00258-8 · Cited by 4

Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19–Associated Cytokine Storm

Langmuir, P. B., Yeleswaram, S., Smith, P., Knorr, B. A., & Squier, P. (2020) · Delaware Journal of Public Health · doi:10.32481/djph.2020.07.015 · Cited by 4

CLINICAL MANAGEMENT OF PATIENTS WITH COVID-19. “LIVE” CLINICAL INSTRUCTION (2021)

Дмитрівна, С. І. (2021) · ДЕРЖАВНА НАУКОВА УСТАНОВА «НАУКОВО-ПРАКТИЧНИЙ ЦЕНТР ПРОФІЛАКТИЧНОЇ І КЛІНІЧНОЇ МЕДИЦИНИ» eBooks · doi:10.31612/covid · Cited by 4

The impact of specific cytokine directed treatment on severe COVID-19

Reuken, P. A., Rüthrich, M. M., Hochhaus, A., Hammersen, J., Bauer, M. W., Rosée, P. G. L., Rosée, F. L., & Stallmach, A. (2021) · Leukemia · doi:10.1038/s41375-021-01411-1 · Cited by 4

Ruxolitinib as a treatment strategy for SARS-CoV-2 pneumonia: clinical experience in a real-world setting

Ovilla-Martínez, R., Cota-Rangel, X., Peña-Celaya, J. D. L., Alvarado-Zepeda, M. A., Jiménez-Sastré, A., Azuara-Forcelledo, H., Rodríguez, B. O., Broca, J. C. P., Molina-Jaimes, A., Muñiz-Carvajal, A. J., et al. (2022) · The Journal of Infection in Developing Countries · doi:10.3855/jidc.15126 · Cited by 4

Delving deeper in the eye of the hurricane: Immunopathogenesis & molecular characterization of cytokine storm in COVID-19, association with disease severity & the therapeutic regimens

Muzaffar, U., Fakiruddin, K. S., Talebiashtiany, Y., & Abdullah, S. (2025) · Cytokine · doi:10.1016/j.cyto.2025.157025 · Cited by 3

Acute severe respiratory syndrome coronavirus-2 treatment overview for pediatrics

Murphy, M. E., Clay, G. M., Danziger‐Isakov, L. A., Schulert, G. S., & Paulsen, G. C. (2020) · Current Opinion in Pediatrics · doi:10.1097/mop.0000000000000983 · Cited by 3

COMPARATIVE ANALYSIS OF DRUG EFFICACY IN THE TREATMENT FOR COVID-19 SEVERE FORMS, BASED ON ATTRIBUTE-BASED STATISTIC METHODS AND ANALYSIS OF DRUG INTERACTIONS

Жукова, О. В., Kagramanyan, I. N., & Хохлов, А. Л. (2021) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2020-8-5-316-324 · Cited by 3

Pearson’s patterns correlational of clinical risks at admissions with hospitalization outcomes during initial COVID-19 outbreak

Li, J., Long, X., Zhang, Q., Fang, X., Luo, H., Fang, F., Lv, X., Zhang, D., Sun, Y., Li, N., et al. (2022) · iScience · doi:10.1016/j.isci.2022.104415 · Cited by 3

Immunomodulatory Agents for Coronavirus Disease-2019 Pneumonia

McManus, D. S., Davis, M. W., Ortiz, A., Britto-Leon, C. J., Cruz, C. S. D., & Topal, J. E. (2022) · Clinics in Chest Medicine · doi:10.1016/j.ccm.2022.11.009 · Cited by 3

The inhibitory activity of Ruxolitinib against COVID-19 major protease enzyme and SARS CoV-2 spike glycoprotein: A molecular docking study

Demirağ, A. D., Çeli̇k, S., ARSLAN, S., Özel, A. E., & Akyüz, S. (2023) · Open Journal of Nano · doi:10.56171/ojn.1134119 · Cited by 3

Serum proteomics hint at an early T-cell response and modulation of SARS-CoV-2-related pathogenic pathways in COVID-19-ARDS treated with Ruxolitinib

Völkel, S., Tarawneh, T. S., Sacher, L., Bhagwat, A. M., Karim, I., Mack, H. I. D., Wiesmann, T., Beutel, B., Hoyer, J. D., Keller, C. A., et al. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1176427 · Cited by 3

Frontiers and hotspots evolution in cytokine storm: A bibliometric analysis from 2004 to 2022

Shen, J., Li, J., Lei, Y., Chen, Z., Wu, L., & Lin, C. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30955 · Cited by 3

Covid-19 Therapy: What Have We Learned In 8 Months?

Adamczyk-Popławska, M., & Kwiatek, A. (2020) · Postępy Mikrobiologii - Advancements of Microbiology · doi:10.21307/pm-2020.59.3.15 · Cited by 3

L1000 connectivity map interrogation identifies candidate drugs for repurposing as SARS-CoV-2 antiviral therapies

Sendama, W. (2020) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2020.11.054 · Cited by 3

Efficacy of Therapeutic Plasma Exchange Alone or in Combination with Ruxolitinib for the Treatment of Penn Class 3 and 4 Cytokine Release Syndrome Complicating COVID-19

Gluck, W. L., Smith, W., Callahan, S. P., Brevetta, R. A., Stenbit, A. E., Martin, J., Blenda, A. V., Arce, S., & Edenfield, W. J. (2021) · Journal of Cellular Immunology · doi:10.33696/immunology.3.100 · Cited by 3

COVID-19: A pluralistic and integrated approach for efficient management of the pandemic

Bouare, N., Minta, D. K., Dabo, A., & Gérard, C. (2022) · World Journal of Virology · doi:10.5501/wjv.v11.i1.20 · Cited by 3

A Review of Potential Therapeutic Strategies for COVID-19

Meng, J., Li, R., Zhang, Z., Wang, J., Huang, Q., Nie, D., Fan, K., Guo, W., Zhao, Z., & Han, Z. (2022) · Viruses · doi:10.3390/v14112346 · Cited by 3

Lines of Treatment of COVID-19 Infection

ElGoly, A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-90595-4.00002-9 · Cited by 3

Janus kinases inhibitors for coronavirus disease-2019: A pairwise and Bayesian network meta-analysis

Niu, J., Lin, Z., He, Z., Yang, X.-J., Qin, L., Feng, S., Guan, L., Zhou, L., & Chen, R. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.973688 · Cited by 3

Managing blood disorders during the Covid-19 pandemic: current pharmacological insights

Karunakaran, P., Nampoothiri, R. V., & Sahu, K. K. (2020) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2020.1841633 · Cited by 3

Interferon-regulated genetic programs and JAK/STAT pathway activate the intronic promoter of the short ACE2 isoform in renal proximal tubulesPreprint

Jankowski, J., Lee, H., Wilflingseder, J., & Hennighausen, L. G. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.01.15.426908 · Cited by 3

Dexamethasone chronotherapy of COVID-19 patients admitted to intensive care unit: an exploratory study

Abusamak, M., Hssain, A. A., Chinta, V. R., Al‐Waeli, H., Yassine, H. M., & Tamimi, F. (2025) · BMC Infectious Diseases · doi:10.1186/s12879-025-11322-6 · Cited by 2

AP2: an indispensable host factor in virus infection

Li, R., Jiang, Y., Wang, X., Zhang, L., & Wang, Y. (2026) · Journal of Virology · doi:10.1128/jvi.02164-25 · Cited by 2

Host‐modifying drugs against COVID ‐19: some successes, but not yet the breakthrough

Brüssow, H. (2021) · Environmental Microbiology · doi:10.1111/1462-2920.15828 · Cited by 2

Pharmacologic Treatment and Management of Coronavirus Disease 2019

Shumaker, A. H., & Bhimraj, A. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.02.001 · Cited by 2

Immunoprofiles of COVID-19 uniquely differentiated from other viruses: A machine learning investigation of multiplex immunoassay data

Kaur, A., & Krishnan, V. V. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae327 · Cited by 2

Calcio-herbal medicine Divya-Swasari-Vati demonstrates acceptable non-clinical safety profile in the repeated-dose 28-day subacute oral toxicity study in Sprague-Dawley rats, under GLP compliance

Balkrishna, A., Sinha, S., & Varshney, A. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1547532 · Cited by 3

Integrative web-based analysis of omics data for study of drugs against SARS-CoV-2

Wang, Z., He, Y. O., Huang, J., & Yang, X. (2021) · Scientific Reports · doi:10.1038/s41598-021-89578-6 · Cited by 2

The Care of the Leukemic Patients in Times of SARS-CoV-2

Karki, N. R., Le, T. T., & Cortes, J. E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01111-0 · Cited by 2

Anti-inflammatory agents other than corticosteroid in SARs-CoV-2 pneumonia

Theerawit, P. (2021) · Clinical Critical Care · doi:10.54205/ccc.v29i.252686 · Cited by 2

Timing of tofacitinib therapy is critical to improving outcomes in severe-critical COVID-19 infection: A retrospective study from a tertiary care hospital

Kodali, R. S., Umesh, S., Selvam, S., Kamath, D. Y., & Shobha, V. (2022) · Medicine · doi:10.1097/md.0000000000030975 · Cited by 2

Best Practices For Administering Monoclonal Antibody Therapy For Coronavirus (COVID-19)

Elsaghir, H., & Adnan, G. (2021) · eCommons - AKU (Aga Khan University) · Cited by 2

The host immune responses to SARS-CoV-2 and therapeutic strategies in the treatment of COVID-19 cytokine storm

Aliyu, M., Mozhgani, S., Gargari, O. K., Yusuf, M. A., & Saboor-Yaraghi, A. A. (2021) · AIMS Allergy and Immunology · doi:10.3934/allergy.2021018 · Cited by 2

In Silico Multi-Target Approach Revealed Potential Lead Compounds as Scaffold for the Synthesis of Chemical Analogues Targeting SARS-CoV-2

Trezza, A., Mugnaini, C., Corelli, F., Santucci, A., & Spiga, O. (2022) · Biology · doi:10.3390/biology11030465 · Cited by 2

Oral Janus kinase inhibitors for treating hospitalized patients with COVID-19: An updated systematic review and meta-analysis of randomized controlled trials

Tang, H.-J., Weng, T.-S., Chen, Y.-H., & Chao, C. (2022) · Journal of Microbiology Immunology and Infection · doi:10.1016/j.jmii.2022.08.005 · Cited by 2

Factors increasing the risk of mortality and morbidity due to coronavirus infection in patients with metabolic syndrome

Enkhtur, A., Yoon, J.-S., & Lee, C. (2020) · Precision and Future Medicine · doi:10.23838/pfm.2020.00121 · Cited by 2

Ruxolitinib-induced extreme thrombocytosis in a COVID-19 patient

Anguiano-Álvarez, V. M., Maza-Larrea, J. A., Rosado-Hernández, F. J., Velasco, G. R., & Izaguirre-Ávila, R. (2021) · Blood Research · doi:10.5045/br.2021.2020245 · Cited by 2

Response to Correspondence: Baricitinib: Impact on Coronavirus Disease 2019 (COVID-19) Coagulopathy? Jorgensen et al

Titanji, B. K., Farley, M. M., Schinazi, R. F., & Marconi, V. C. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1210 · Cited by 2

A Systematic Review and Network Meta-Analysis for COVID-19 TreatmentsPreprint

Zhang, C., Jin, H., Wen, Y., & Yin, G. (2020) · medRxiv · doi:10.1101/2020.12.21.20248621 · Cited by 2

Proactive anti-inflammatory therapy in the advanced stages of a new coronavirus infection. Main results of the inpatient phase of the COLORIT study (Colchicin vs. Ruxolitinib and secukinumab in an open, prospective, randomized trial in patients with novel coronavirus infection COVID-19)

Mareev, V. Y., Orlova, Y. A., Plisuk, A. G., Павликова, Е. П., Akopyan, Z. A., Мацкеплишвили, С. Т., Малахов, П. С., Krasnova, T. N., Seredenina, E. M., Potapenko, A. V., et al. (2022) · Kardiologiia · doi:10.18087/cardio.2022.12.n2316 · Cited by 1

T cell responses to SARS-COV-2

Khadri, L., Ziraksaz, M. H., Barekzai, A. B., & Ghauri, B. (2023) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2023.06.001 · Cited by 1

Network Pharmacology and Experimental Validation of Qingwen Baidu Decoction Therapeutic Potential in COVID-19-related Lung Injury

Yang, J., Zhang, Z., Liu, H., Wang, J., Xie, S., Li, P., Wen, J., Wei, S., Li, R., Ma, X., et al. (2023) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/0113862073236899230919062725 · Cited by 1

Adverse drug reactions associated with COVID-19 management

Chavda, V. P., Dodiya, P., & Apostolopoulos, V. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03137-0 · Cited by 1

The development of therapeutics and vaccines against COVID-19.

Zhao, T., Wang, Z., Tong, M., & Fei, Y. (2024) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2024.116643 · Cited by 1

COVID-19 therapy: from myths to reality and hopes

Bozrova, S. V., Drutskaya, M. S., & Nedospasov, S. A. (2020) · Medical Immunology (Russia) · doi:10.15789/1563-0625-ctf-2095 · Cited by 1

In Silico Evaluation for the Inhibitory Action of Curcumin Derivatives on the SARS-CoV-2 Proteins

Jaradat, A., Salameh, Y., Zaid, H., & Shanak, S. (2022) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2022.104007 · Cited by 1

Managing Covid-19 in patients with heart failure: current status and future prospects

Prameswari, H. S., Putra, I. C. S., Raffaello, W. M., Nathaniel, M., Suhendro, A. S., Khalid, A. F., & Pranata, R. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2132230 · Cited by 1

Therapeutics for COVID-19

Krishnaswami, S., de la Peña, A., Kim, S., & Menon, S. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-87539-4.00016-6 · Cited by 1

Major determinant factors of pediatric COVID-19 severity; a single center study

Ali, H. A. (2023) · Egyptian Pediatric Association Gazette · doi:10.1186/s43054-023-00161-2 · Cited by 1

Treatment of the cytokine storm in COVID-19: review of clinical pharmacology

Sapriati, A. N., Rahmawati, F., & Nuryastuti, T. (2023) · Jurnal Sains Farmasi & Klinis · doi:10.25077/jsfk.10.2.162-183.2023 · Cited by 1

Pulmonary involvement and cytochemical storm: beyond SARS-CoV-2 pneumoniae

Para, O., D’Agostino, M., & Mezzasalma, F. (2020) · Italian Journal of Medicine · doi:10.4081/itjm.2020.1401 · Cited by 1

Terapias imunossupressoras no tratamento de COVID-19: uma revisão integrativa da literatura / Immunosuppressive therapies treatments for COVID-19: a literature review

Machado, A. B. S., Alves, A. F., Araújo, H. R., Barros, J. F., Teixeira, L. S. F., & de Moura, R. S. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n1-288 · Cited by 1

Perspectiva hematológica en el tratamiento de pacientes con COVID-19: rol de los tratamientos antiinflamatorios

Rojas, P., & Mauricio Sarmiento, M. (2020) · Revista médica de Chile · doi:10.4067/s0034-98872020001101640 · Cited by 1

The Effectiveness of Remdesivir versus Ruxolitinib as Covid-19 Supportive Management: Systematic Review, Meta-Analysis

Fhatonah, N., Ma’sum, Dewianti, Z. P., Nuraini, N., & Rusdiana, N. (2021) · Advances in health sciences research/Advances in Health Sciences Research · doi:10.2991/ahsr.k.210115.114 · Cited by 1

Finding a prospective dual-target drug for the treatment of coronavirus disease by theoretical study

Mahnam, K., & Ghobadi, Z. (2021) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2021.1973910 · Cited by 1

Interleukin Receptor Antagonists and Janus Kinase Inhibitors Repurposed for Treatment of COVID-19

Tandon, R., Paul, K., Tandon, N., & Luxami, V. (2022) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557522999220128150814 · Cited by 1

Terapias imunossupressoras no tratamento de COVID-19: uma revisão integrativa da literatura / Immunosuppressive therapies treatments for COVID-19: a literature review

Machado, A. B. S., Alves, A. F., Araújo, H. R., Barros, J. F., Teixeira, L. S. F., & de Moura, R. S. (2021) · Brazilian Journal of Health Review · doi:10.34119/bjhrv4n2-087 · Cited by 1

Nanomedicine “New Food for an Old Mouth”: Novel Approaches for the Treatment of COVID-19

Handali, S., Haririan, I., Vaziri, M., & Dorkoosh, F. A. (2022) · Drug Delivery Letters · doi:10.2174/2210303112666220829125054 · Cited by 1

COVID-19 and its genomic variants: molecular pathogenesis and therapeutic interventions

Manna, P. R., Gray, Z. C., Sikdar, M., & Reddy, H. (2022) · EXCLI journal · doi:10.17179/excli2022-5315 · Cited by 1

Immune-Based Therapy for Hospitalized Patients With COVID-19 and Risk of Secondary Infections: A Systematic Review and Meta-analysis

Kabbani, D., Sonpar, A., Weyant, R. B., Lau, K. C. K., Robbins, M., Campbell, S., Doucette, K. E., Abraldeṣ, J. G., Lotfi, T., Chaktoura, M., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac655 · Cited by 1

Efficacy of Additional Corticosteroids After Dexamethasone Treatment for Moderate to Severe COVID-19: An Observational Study

Fukuda, Y., Mochizuki, K., Ijichi, M., Homma, T., Tanaka, A., & Sagara, H. (2023) · Cureus · doi:10.7759/cureus.43179 · Cited by 1

Comparative efficacy and safety of current drugs against COVID-19: A systematic review and network meta-analysisPreprint

Li, Y., & He, W. (2020) · medRxiv · doi:10.1101/2020.11.16.20232884 · Cited by 1

What's new in critical illness and injury science? An evidence-based analysis of the impact of Janus Kinase inhibitors on 28-day mortality in patients admitted with COVID-19

Miller, A., & D'Silva, Y. A. (2021) · International Journal of Critical Illness and Injury Science · doi:10.4103/ijciis.ijciis_80_21 · Cited by 1

COVID-19

(2020) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2020.19.3 · Cited by 1

Can We Really Trust the Findings of the COVID-19 Research? Quality Assessment of Randomized Controlled Trials Published on COVID-19Preprint

Joshy, A. S., Thomas, C., Surendran, S., & Undela, K. (2022) · medRxiv · doi:10.1101/2022.04.15.22273881 · Cited by 1

Protein Kinase Antagonists

Laurence, A. D. J., Gadina, M., Schwartzberg, P. L., & O’Shea, J. J. (2023) · Elsevier eBooks · doi:10.1016/b978-0-7020-8165-1.00085-x · Cited by 1

Effects of Jak Inhibitors in Adults Hospitalized Due to Covid-19: A Systematic Review and Individual Participant Data Meta-Analysis of Randomized Clinical TrialsPreprint

Amstutz, A., Schandelmaier, S., Ewald, H., Speich, B., Schwenke, J. M., Schönenberger, C., Schobinger, S., Agoritsas, T., Tomashek, K. M., Nayak, S., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4974193 · Cited by 1

SÍNDROME DE BURNOUT EM ESTUDANTES DE FISIOTERAPIA: REVISÃO SISTEMÁTICA COM META-ANÁLISE

Mesquita, C. P., Praxedes, L. D. A., & do Nascimento, F. M. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0001073

Double Lock the COVID 19: Inhibit SARS COV 2 Replication and Suppress Inflammation Cytokine Level by the Golden CompoundsPreprint

He, Z., Zhang, C., Du, Z., Zhao, W., Niu, W., Gao, Y., Dong, Y., Fan, J., He, B., Cao, P., et al. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12560276.v1

Hematologic Therapies Being Studied for Coronavirus: Capitalizing on Progress

Michaelis, L. C., & Monahan, K. (2020) · The Hematologist · doi:10.1182/hem.v17.4.12884901941

Rational pharmacological approach to clinical studies for the treatment of SARS-COV-2 infection

Rabêlo, A. D. D. S., Souza, G. G. D., de Sousa, R. R., & da Costa, C. L. S. (2020) · Enfermagem Brasil · doi:10.33233/eb.v19i4.4349

Effectiveness of Antiviral and Immunomodulatory Agents in the Treatment of COVID-19: A Systematic Review

Khodashahi, R., Naderi, H., Bojdy, A., & Khodashahi, M. (2020) · Current Respiratory Medicine Reviews · doi:10.2174/1573398x16999201202121247

Manejo clínico de pacientes com doenças reumáticas imunomediadas durante a pandemia da COVID-19

Pinheiro, M. A. A., & Pileggi, G. S. (2020) · Revista Paulista de Reumatologia · doi:10.46833/reumatologiasp.2020.19.3.27-35 · Cited by 1

Insights into the molecular mechanism of anticancer drug ruxolitinib repurposable in COVID-19 therapyPreprint

Mandal, M. D., & Mandal, S. (2021) · medRxiv · doi:10.1101/2020.12.29.20248986

A Generalized Overview of the Possible Pharmacotherapy and Treatments against SARS-CoV-2

Islam, S. S., Alam, S., Rajib, T. K., Akhter, N., & Islam, M. Z. (2021) · Journal of Contemporary Studies in Epidemiology and Public Health · doi:10.30935/jconseph/9367

Pharmacological Treatment for Patients with Coronavirus Disease 2019: Systematic Review of Randomized Controlled TrialsPreprint

Abu-Raya, B., Mijović, H., Donken, R., Cabrera, A., Kitchin, V., Chow, R., Leishman, R., Pan, C., Paquette, V., Roberts, A. D., et al. (2020) · doi:10.21203/rs.3.rs-90401/v1

Repositionnement des antinéoplasiques utilisés en hématologie dans le traitement du COVID-19

Tazi, I. (2021) · Bulletin du Cancer · doi:10.1016/j.bulcan.2020.12.009

Possíveis tratamentos farmacológicos em fase de estudos para pacientes sintomáticos de COVID-19:Uma revisão integrativa

Silva, D. G., Bartaquini, R. T., Pedrosa, B. M., Ribeiro, C. H. M. A., & Prete, A. C. L. (2021) · Research Society and Development · doi:10.33448/rsd-v10i6.15579

Therapeutic approaches to tackle COVID-19: An overview

Palatty, P. L., David, R., Philip, B. M., Sunny, C., Mamatha, J., Vanditha, S., & George, D. M. (2021) · Indian Journal of Pharmacy and Pharmacology · doi:10.18231/j.ijpp.2021.020

Learning COVID-19 network from literature databases using core decomposition

Guo, Y. (2021) · UVic’s Research and Learning Repository (University of Victoria)

Repurposing Ruxolitinib in Combating COVID-19: A Mini-review

Begum, I., Murthuza, F., Iqbaluddin, J. S., & Arsal, H. F. (2021) · New Emirates Medical Journal · doi:10.2174/0250688202666210715141439

OS EFEITOS DA TERAPIA DO EXERCÍCIO NO TRATAMENTO DOS INDIVÍDUOS COM SOROLOGIA POSITIVA PARA O VÍRUS DA IMUNODEFICIÊNCIA HUMANA: REVISÃO DE LITERATURA

Pereira, D. M. D. M., da Silva, S. A., de Oliveira, J. R. S., & Passos, P. P. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0001071

POTENCIALIDADES DE CÉLULAS-TRONCO APLICADAS NA ODONTOLOGIA

Peixoto, N. L., dos Anjos, G. C., Emerenciano, D. P., & Maciel, M. A. M. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0001087

TOXOPLASMOSE: RELATO DE CASO DE UMA FEBRE DE ORIGEM INDETERMINADA

Gribel, C. R. N., Sofal, J. C., Salomão, J. A. L., de Medeiros, M. L., Silva, M. R., & Gribel, N. S. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0001062

ATUAÇÃO DO ENFERMEIRO NA PREVENÇÃO DE PNEUMONIA ASSOCIADA À VENTILAÇÃO MECÂNICA EM TERAPIA INTENSIVA

Oliveira, J. G., Knupp, N., Ribeiro, L. H. D. S., da Silva, L. M. S., de Mesquita, G. N., Alves, A. L. N., Ribeiro, L. R., Cardoso, R. L., & Gomes, D. M. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0001078

ESÔFAGO NEGRO EM PACIENTE RECEPTOR DE TRANSPLANTE RENAL: UM RELATO DE CASO

Pires, H. H. G., Rodrigues, B. S. C., Simões, F. F., Braga, M. S., Amaral, A. R., da Silva, S. G. T., & Morais, G. S. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0001063

USO DE VARENICLINA ASSOCIADA A SINTOMAS DE PSICOSE EM PACIENTE SEM TRANSTORNO PSIQUIATRICO PRÉVIO: UM RELATO DE CASO

Bobato, B. F., Dib, E. C. S., Sprung, H. A., Rota, V. L. G., & Laux, A. L. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0001066

COMPORTAMENTO SEXUAL E INFECÇÕES SEXUALMENTE TRANSMISSÍVEIS EM MULHERES QUE FAZEM SEXO COM MULHERES NO BRASIL

Fontes, G. D. Q., Aguiar, A. R., Gonçalves, A. S. S., Menezes, J. P. D. L., Santos, V. T. A., de Araújo, R. A. S., & Dias, J. M. G. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0001065

ANÁLISE DE INDICADORES RELACIONADOS À PRESCRIÇÃO DE NUTRIÇÃO PARENTERAL EM UM HOSPITAL UNIVERSITÁRIO DE BELÉM – PARÁ

Naves, J. D. O., Cesario, M. S. A., Veloso, S. M. D. A., & Moraes, A. L. S. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0001080

TDAH E O USO PROLONGADO DAS MÍDIAS SOCIAIS

de Oliveira, R. C., da Silva, J. V., & Cardoso, V. L. D. S. (2021) · Brazilian Journals Editora eBooks · doi:10.35587/brj.ed.0001086

Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial

Han, M. K., Antila, M., Ficker, J. H., Гордеев, И. Г., Guerreros, A. G., López‐Bernús, A., Roquilly, A., Sifuentes‐Osornio, J., Tabak, F., Teijeiro, R., et al. (2022) · The Lancet Rheumatology · doi:10.1016/s2665-9913(22)00044-3 · Cited by 48

Abstract PO-002: RUXCOVID: A phase 3, randomized, placebo-controlled study evaluating the efficacy and safety of ruxolitinib in patients with COVID-19–associated cytokine storm

Han, M. K., Ignacio, R. B., López‐Bernús, A., Milger, K., Nyaku, A. N., Parker, B., Potter, V. T., Savic, S., Campello-Iddison, V., Cao, W., et al. (2020) · Clinical Cancer Research · doi:10.1158/1557-3265.covid-19-po-002 · Cited by 3

Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis

Quiros, J., Ross-Comptis, J., Hathaway, D., Sarfraz, A., Sarfraz, Z., Grigoryan, Z., Romero, K. A., Gapizov, A., Príncipe-Meneses, F. S., Somagutta, M. K. R., et al. (2021) · Infection and Chemotherapy · doi:10.3947/ic.2020.0126 · Cited by 16

Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study

Vannucchi, A. M., Sordi, B., Morettini, A., Nozzoli, C., Poggesi, L., Pieralli, F., Bartoloni, A., Atanasio, A., Miselli, F., Paoli, C., et al. (2020) · Leukemia · doi:10.1038/s41375-020-01018-y · Cited by 73

The impact of Ruxolitinib therapy on mortality in Coronavirus disease-2019 patients treated on intensive care unit – a retrospective data analysis

Mathusek, A. (2025) · open_UMR Marburg DSpace 10.0 (Philipps-Universität Marburg) · doi:10.17192/z2025.0426